{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:11:15Z","timestamp":1788459075641,"version":"build-2803163510"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Endothelial Activation and Stress Index (EASIX) has been proposed as a prognostic factor of adverse events or survival in hematological malignancies. Endothelial dysfunction has been associated with complications following stem cell transplantation and chimeric antigen receptor (CAR)-T therapy. This retrospective cohort study evaluated the utility of the EASIX score as a prognostic factor of cytokine release syndrome (CRS) in multiple myeloma\/light-chain amyloidosis (MM\/AL amyloidosis; N = 69) and large B-cell lymphoma (LBCL) cohorts (N = 65). Occurrence of CRS grade \u22653 was the primary endpoint. For both cohorts, the EASIX and simplified EASIX (s-EASIX) scores were calculated at four different time points before CAR-T infusion to assess its prognostic value. In the MM\/AL amyloidosis cohort, neither EASIX nor s-EASIX scores calculated at any time point were associated with the occurrence of CRS grade \u22653. In the LBCL cohort, EASIX and s-EASIX scores measured before lymphodepletion (EASIX-pre and s-EASIX-pre) showed a significant relationship with CRS grade \u22653 (odds ratio [OR] = 1.06 and OR = 1.05, respectively). The cutoff value of 1.835 for EASIX-pre was associated with 4.59-fold increased OR of CRS grade \u22653 (95% confidence interval [CI]: 1.13\u201321.84), whereas s-EASIX-pre cutoff equaled 2.134 and was associated with 4.13-fold increased OR of CRS grade \u22653 (95% CI: 1.01\u201317.93). However, after internal validation with bootstrapping, the significance was lost both for the EASIX-pre and s-EASIX-pre cutoff. The presented findings indicate that the EASIX scores fail to predict CRS in MM\/amyloidosis CAR-T patients, whereas they can be implemented as CRS grade \u22653 predictors in LBCL CAR-T patients.<\/jats:p>","DOI":"10.2478\/aite-2024-0018","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T15:15:20Z","timestamp":1726413320000},"source":"Crossref","is-referenced-by-count":8,"title":["Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients \u2013 A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts"],"prefix":"10.2478","volume":"72","author":[{"given":"Jaromir","family":"Tomasik","sequence":"first","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine , Medical University of Warsaw , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy , Hadassah Medical Center , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Grisariu","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy , Hadassah Medical Center , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Elias","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy , Hadassah Medical Center , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Zimran","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy , Hadassah Medical Center , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy , Hadassah Medical Center , Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz W.","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine , Medical University of Warsaw , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"2026060500585265225_j_aite-2024-0018_ref_001","doi-asserted-by":"crossref","unstructured":"Almici C, Skert C, Verardi R et al (2014) Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation 98:706\u2013712. https:\/\/doi.org\/10.1097\/tp.0000000000000385","DOI":"10.1097\/TP.0000000000000385"},{"key":"2026060500585265225_j_aite-2024-0018_ref_002","doi-asserted-by":"crossref","unstructured":"Asherie N, Kfir-Erenfeld S, Avni B et al (2023) Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial. Haematologica 108:1827\u20131839. https:\/\/doi.org\/10.3324\/haematol.2022.281628","DOI":"10.3324\/haematol.2022.281628"},{"key":"2026060500585265225_j_aite-2024-0018_ref_003","doi-asserted-by":"crossref","unstructured":"Biedermann BC, Sahner S, Gregor M et al (2002) Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359:2078\u20132083. \nhttps:\/\/doi.org\/10.1016\/s0140-6736(02)08907-9","DOI":"10.1016\/S0140-6736(02)08907-9"},{"key":"2026060500585265225_j_aite-2024-0018_ref_004","doi-asserted-by":"crossref","unstructured":"Cordes S, Mokhtari Z, Bartosova M et al (2021) Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica 106:2147\u20132160. https:\/\/doi.org\/10.3324\/haematol.2020.253716","DOI":"10.3324\/haematol.2020.253716"},{"key":"2026060500585265225_j_aite-2024-0018_ref_005","doi-asserted-by":"crossref","unstructured":"Eelen G, de Zeeuw P, Treps L et al (2018) Endothelial cell metabolism. Physiol Rev 98:3\u201358. https:\/\/doi.org\/10.1152\/physrev.00001.2017","DOI":"10.1152\/physrev.00001.2017"},{"key":"2026060500585265225_j_aite-2024-0018_ref_006","doi-asserted-by":"crossref","unstructured":"Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201331. https:\/\/doi.org\/10.1038\/nm0195-27","DOI":"10.1038\/nm0195-27"},{"key":"2026060500585265225_j_aite-2024-0018_ref_007","doi-asserted-by":"crossref","unstructured":"Greenbaum U, Strati P, Saliba RM et al (2020) The EASIX (Endothelial Activation and Stress Index) score predicts for CAR T related toxicity in patients receiving axicabtagene ciloleucel (axi-cel) for non-Hodgkin lymphoma (NHL). Blood 136(Supplement 1):-17\u201318. https:\/\/doi.org\/10.1182\/blood-2020-141388","DOI":"10.1182\/blood-2020-141388"},{"key":"2026060500585265225_j_aite-2024-0018_ref_008","doi-asserted-by":"crossref","unstructured":"Greenbaum U, Strati P, Saliba RM et al (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5:2799\u20132806. https:\/\/doi.org\/10.1182\/bloodadvances.2021004575","DOI":"10.1182\/bloodadvances.2021004575"},{"key":"2026060500585265225_j_aite-2024-0018_ref_009","doi-asserted-by":"crossref","unstructured":"Gust J, Ponce R, Liles WC et al (2020) Cytokines in CAR T cell-associated neurotoxicity. Front Immunol 11:577027. https:\/\/doi.org\/10.3389\/fimmu.2020.577027","DOI":"10.3389\/fimmu.2020.577027"},{"key":"2026060500585265225_j_aite-2024-0018_ref_010","doi-asserted-by":"crossref","unstructured":"Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood 130:2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","DOI":"10.1182\/blood-2017-06-793141"},{"key":"2026060500585265225_j_aite-2024-0018_ref_011","doi-asserted-by":"crossref","unstructured":"Korell F, Penack O, Mattie M et al (2022) EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study. Front Immunol 13:877477. https:\/\/doi.org\/10.3389\/fimmu.2022.877477","DOI":"10.3389\/fimmu.2022.877477"},{"key":"2026060500585265225_j_aite-2024-0018_ref_012","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","DOI":"10.1016\/j.bbmt.2019.02.027"},{"key":"2026060500585265225_j_aite-2024-0018_ref_013","doi-asserted-by":"crossref","unstructured":"Lee J, Upreti HV, Sannareddy A et al (2024) Pre-lymphodepletion Endothelial Activation and Stress Index as a predictor of clinical outcomes in B-cell maturation antigen CAR T therapy for multiple myeloma. Transplantat Cell Ther 30(Supplement):S221\u2013S222. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.288","DOI":"10.1016\/j.jtct.2023.12.288"},{"key":"2026060500585265225_j_aite-2024-0018_ref_014","doi-asserted-by":"crossref","unstructured":"Luft T, Benner A, Jodele S et al (2017) EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 4:e414\u2013e423. \nhttps:\/\/doi.org\/10.1016\/s2352-3026(17)30108-4","DOI":"10.1016\/S2352-3026(17)30108-4"},{"key":"2026060500585265225_j_aite-2024-0018_ref_015","doi-asserted-by":"crossref","unstructured":"Luft T, Benner A, Terzer T et al (2020) EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 55:553\u2013561. https:\/\/doi.org\/10.1038\/s41409-019-0703-1","DOI":"10.1038\/s41409-019-0703-1"},{"key":"2026060500585265225_j_aite-2024-0018_ref_016","doi-asserted-by":"crossref","unstructured":"Mariotti J, Magri F, Giordano L et al (2023) EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant 58:247\u2013256. https:\/\/doi.org\/10.1038\/s41409-022-01874-5","DOI":"10.1038\/s41409-022-01874-5"},{"key":"2026060500585265225_j_aite-2024-0018_ref_017","doi-asserted-by":"crossref","unstructured":"Menzel L, H\u00f6pken UE, Rehm A (2020) Angiogenesis in lymph nodes is a critical regulator of immune response and lymphoma growth (Review). Front Immunol 11:591741. https:\/\/doi.org\/10.3389\/fimmu.2020.591741","DOI":"10.3389\/fimmu.2020.591741"},{"key":"2026060500585265225_j_aite-2024-0018_ref_018","doi-asserted-by":"crossref","unstructured":"Merz A, Germing U, Kobbe G et al (2019) EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 9:85. https:\/\/doi.org\/10.1038\/s41408-019-0247-z","DOI":"10.1038\/s41408-019-0247-z"},{"key":"2026060500585265225_j_aite-2024-0018_ref_019","doi-asserted-by":"crossref","unstructured":"Molema G (2010) Heterogeneity in endothelial responsiveness to cytokines, molecular causes, and pharmacological consequences. Semin Thromb Hemost 36:246\u2013264. https:\/\/doi.org\/10.1055\/s-0030-1253448","DOI":"10.1055\/s-0030-1253448"},{"key":"2026060500585265225_j_aite-2024-0018_ref_020","doi-asserted-by":"crossref","unstructured":"Page AV, Liles WC (2013) Biomarkers of endothelial activation\/dys-function in infectious diseases. Virulence 4:507\u2013516. https:\/\/doi.org\/10.4161\/viru.24530","DOI":"10.4161\/viru.24530"},{"key":"2026060500585265225_j_aite-2024-0018_ref_021","doi-asserted-by":"crossref","unstructured":"Palomo M, Diaz-Ricart M, Carbo C et al (2010) Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 16:985\u2013993. https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.008","DOI":"10.1016\/j.bbmt.2010.02.008"},{"key":"2026060500585265225_j_aite-2024-0018_ref_022","doi-asserted-by":"crossref","unstructured":"Park S, Go SI, Lee GW (2022) The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma. BMC Cancer 22:816. https:\/\/doi.org\/10.1186\/s12885-022-09915-4","DOI":"10.1186\/s12885-022-09915-4"},{"key":"2026060500585265225_j_aite-2024-0018_ref_023","doi-asserted-by":"crossref","unstructured":"Penack O, Henke E, Suh D et al (2010) Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst 102:894\u2013908. https:\/\/doi.org\/10.1093\/jnci\/djq172","DOI":"10.1093\/jnci\/djq172"},{"key":"2026060500585265225_j_aite-2024-0018_ref_024","doi-asserted-by":"crossref","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR et al (2021) Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv 5: 3397\u20133406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885","DOI":"10.1182\/bloodadvances.2020003885"},{"key":"2026060500585265225_j_aite-2024-0018_ref_025","doi-asserted-by":"crossref","unstructured":"Rajendran P, Rengarajan T, Thangavel J et al (2013) The vascular endothelium and human diseases. Int J Biol Sci 9:1057\u20131069. https:\/\/doi.org\/10.7150\/ijbs.7502","DOI":"10.7150\/ijbs.7502"},{"key":"2026060500585265225_j_aite-2024-0018_ref_026","doi-asserted-by":"crossref","unstructured":"Riesner K, Shi Y, Jacobi A et al (2017) Initiation of acute graft-versus-host disease by angiogenesis. Blood 129:2021\u20132032. https:\/\/doi.org\/10.1182\/blood-2016-08-736314","DOI":"10.1182\/blood-2016-08-736314"},{"key":"2026060500585265225_j_aite-2024-0018_ref_027","doi-asserted-by":"crossref","unstructured":"Sidana S, Hosoya H, Jensen A et al (2023) Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer J 13:158. https:\/\/doi.org\/10.1038\/s41408-023-00929-0","DOI":"10.1038\/s41408-023-00929-0"},{"key":"2026060500585265225_j_aite-2024-0018_ref_028","doi-asserted-by":"crossref","unstructured":"Song GY, Jung SH, Kim K et al (2020) Endothelial Activation and Stress Index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer 20:803. https:\/\/doi.org\/10.1186\/s12885-020-07317-y","DOI":"10.1186\/s12885-020-07317-y"},{"key":"2026060500585265225_j_aite-2024-0018_ref_029","doi-asserted-by":"crossref","unstructured":"Thanhakun R, Wudhikarn K, Bunworasate U et al (2023) Endothelial Activation and Stress Index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group. Ann Hematol 102:3533\u20133541. https:\/\/doi.org\/10.1007\/s00277-023-05437-6","DOI":"10.1007\/s00277-023-05437-6"},{"key":"2026060500585265225_j_aite-2024-0018_ref_030","doi-asserted-by":"crossref","unstructured":"Tomasik J, Drozd-Soko\u0142owska J, Kacprzyk P et al (2023) Tisagenlecleucel CAR-T for relapsed\/refractory diffuse large B-cell lymphoma, one therapy; two different clinical presentations. An urgent need to design adverse event predictors. Acta Haematologica Polonica 54:100\u2013103. https:\/\/doi.org\/10.5603\/AHP.a2023.0018","DOI":"10.5603\/AHP.a2023.2018"},{"key":"2026060500585265225_j_aite-2024-0018_ref_031","doi-asserted-by":"crossref","unstructured":"Trepels T, Zeiher AM, Fichtlscherer S (2006) The endothelium and inflammation. Endothelium 13:423\u2013429. https:\/\/doi.org\/10.1080\/10623320601061862","DOI":"10.1080\/10623320601061862"},{"key":"2026060500585265225_j_aite-2024-0018_ref_032","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026060500585265225_j_aite-2024-0018_ref_033","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhu L, Zhang H et al (2022) CAR-T cell therapy in hemato-logical malignancies: current opportunities and challenges. Front Immunol 13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153","DOI":"10.3389\/fimmu.2022.927153"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aite-2024-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:59:07Z","timestamp":1780621147000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aite-2024-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,14]]},"published-print":{"date-parts":[[2024,1,1]]}},"alternative-id":["10.2478\/aite-2024-0018"],"URL":"https:\/\/doi.org\/10.2478\/aite-2024-0018","relation":{},"ISSN":["1661-4917"],"issn-type":[{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"20240018"}}